Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
P Chin
Observed name:
P. Chin
Institution:
Genentech
Observed institutions:
Genentech,
Novartis (United States)
ORCID:
0009-0008-7500-7254
Observed ORCID:
0009-0008-7500-7254
OpenAlex ID:
A5114051707
Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis - results of the placebo-controlled, double-blind, Phase III ORATORIO study
2015
·
Xavier Montalbán
, Bernhard Hemmer
, et al.
·
mediaTUM (Technical University of Munich)
·
57
Fingolimod effect on brain volume loss independently contributes to its effect on disability
2015
·
MP Sormani
, N De Stefano
, et al.
·
Multiple Sclerosis Journal
·
33
P 2 Effect of ocrelizumab on humoral immunity markers in the phase iii, double-blind, double-dummy, IFN β -1a–controlled OPERA I and OPERA II studies
2017
·
T. Ziemssen
, A. Bar-Or
, et al.
·
Clinical Neurophysiology
·
13
P 1 Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis – analysis of the phase III, double-blind, double-dummy, interferon beta-1a- controlled OPERA I and OPERA II studies
2017
·
T. Ziemssen
, D.L. Arnold
, et al.
·
Clinical Neurophysiology
·
2
Categorical change in T2 lesion volume and clinical outcomes in the Phase III FREEDOMS and its extension study, evaluating fingolimod in patients with relapsing-remitting multiple sclerosis
2014
·
D. Jeffery
, E.V.D. Cantogno
, et al.
·
Multiple Sclerosis and Related Disorders
·
2
Consistent reduction in the annualized rate of brain volume loss across phase 3 core and extension trials of fingolimod in relapsing multiple sclerosis
2014
·
E.W. Radue
, T. Sprenger
, et al.
·
Multiple Sclerosis and Related Disorders
·
2
Four-year Expanded Disability Status Scale (EDSS) outcomes in patients treated with fingolimod in the Phase 3 and extension trial program
2014
·
Bruce Cree
, P. Chin
, et al.
·
Multiple Sclerosis and Related Disorders
·
1
Video-based paired-comparison ranking: A validation tool for fine grained measures of motor dysfunction in multiple sclerosis
2014
·
Jacobus Burggraaf
, Jonas F. Dorn
, et al.
·
1
Internal Consistency and Construct Validity of Patient-Reported Outcomes in Primary Progressive Multiple Sclerosis
2016
·
X Montalban
, J Wolinsky
, et al.
·
Value in Health
Infrared depth sensor based automated classification of motor dysfunction in multiple sclerosis – a proof-of-concept study
2014
·
Jacobus Burggraaf
, Christian P. Kamm
, et al.
Show more works
View as search
Works count:
10
Citation count:
111
H-index:
3
I10-index:
3
Year
Topic
Type